ARQT · Arcutis Biotherapeutics Inc
United States · RS rating 74 · As of 2026-10-14
| Price | 26.41 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 74 / 95 / 44 / 80 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 52 / 39 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +116.7% |
| Sales growth Q/Q | +30.5% |
| Distance from 52-week high | +15.3% |
| Market cap (USD) | $2.9B |